Advances in Stem Cell Therapy for Diabetic Foot Ulcers.
Wang B., Zhao G., Zhang J., Chen W., Yang S., Sun Y.
Narrative Review on Diabetic Foot, Chronic Inflammation, published in Diabetes Metab Syndr Obes (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Diabetes Metab Syndr Obes (2025)
- Country
- New Zealand
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41185855
- PMCID
- PMC12579874
- DOI
- 10.2147/DMSO.S564011
- Citations
- 1
Abstract (original English)
Diabetic foot ulcers (DFU) are a severe and recurrent complication of diabetes that significantly increase the risk of infection, amputation, and mortality. Conventional therapies often fail to achieve complete healing due to the complex microenvironment characterized by ischemia, chronic inflammation, neuropathy, and oxidative stress. Stem-cell-based interventions offer a multifaceted therapeutic strategy by promoting angiogenesis, modulating immune responses, reducing oxidative damage, and enhancing extracellular matrix remodeling. This review provides a comprehensive analysis of major stem-cell sources including bone marrow-derived mesenchymal stem cells (BM-MSCs), adipose-derived stem cells (ADSCs), umbilical cord blood mesenchymal stem cells (UCB-MSCs), and induced pluripotent stem cells (iPSCs). Comparative evaluation highlights that ADSCs are advantageous for autologous use and easy harvesting, BM-MSCs have the longest clinical track record, UCB-MSCs offer low immunogenicity for allogeneic applications, and iPSCs provide customizable options but require genomic stability monitoring. Increasing evidence supports the use of cell-free approaches, particularly exosome and secretome-based therapies, which reproduce stem-cell paracrine effects while minimizing ethical and safety concerns. Integration of these biologics with advanced biomaterials and nanoplatforms further enhan
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level AMeta-analysisPubMed
Efficacy of Stem Cell-Derived Exosomes in Promoting Diabetic Foot Ulcer Healing: A Meta-Analysis of Preclinical Animal Studies.
Meta-analysis on Diabetic Foot, Chronic Wound, published in J Diabetes Res (2026) — summary generated from the PubMed abstract.
- 2026
J Diabetes Res - Level AMeta-analysisEurope PMC
Bone marrow-derived mesenchymal stem cells combined with intramuscular injection promote the healing of diabetic foot ulcers: a systematic review and meta-analysis
Meta-analysis with a reported sample of 2059 on Diabetic Foot, Chronic Wound, published in Front Endocrinol (Lausanne) (2026) — summary generated from the PubMed abstract.
- 2026
- n = 2059
Front Endocrinol (Lausanne) - Level AMeta-analysisEurope PMC
Comparative efficacy of advanced therapeutic modalities for diabetic foot ulcers: a systematic review and meta-analysis including NPWT, stem cells, ESWT, and bioengineered treatments
Meta-analysis on Diabetic Foot, published in Front Bioeng Biotechnol (2026) — summary generated from the PubMed abstract.
- 2026
Front Bioeng Biotechnol - Level AMeta-analysisPubMed
Therapeutic potential of adipose-derived stem cells for diabetic foot ulcers: a systematic review and meta-analysis.
Meta-analysis on Diabetic Foot, Chronic Wound, published in Diabetol Metab Syndr (2025) — summary generated from the PubMed abstract.
- 2025
Diabetol Metab Syndr6 citations - Level AMeta-analysisPubMed
A meta-analysis on application and prospect of cell therapy in the treatment of diabetes mellitus.
Meta-analysis on Diabetic Foot, Autoimmune Research, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.
- 2025
Stem Cell Res Ther - Level AMeta-analysisEurope PMC
Comparison of the efficacy of 12 interventions in the treatment of diabetic foot ulcers: a network meta-analysis
Meta-analysis with a reported sample of 356 on Diabetic Foot, Chronic Wound, published in PeerJ (2025) — summary generated from the PubMed abstract.
- 2025
- n = 356
PeerJ1 citations